Harborside


Avicanna Inc.

TSE: AVCN


Canadian symbol: AVCN.TO
US symbol: AVCNF

Currency in CAD

Valuation Measures

Market Cap (intraday) 543.42M
Enterprise Value 339.78M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)21.98
Price/Book (mrq)2.19
Enterprise Value/Revenue 320.14
Enterprise Value/EBITDA 7-2.24

Trading Information

Stock Price History

Beta (5Y Monthly) 2.17
52-Week Change 3-28.95%
S&P500 52-Week Change 336.19%
52 Week High 31.8900
52 Week Low 30.7500
50-Day Moving Average 31.0797
200-Day Moving Average 31.1329

Share Statistics

Avg Vol (3 month) 39.09k
Avg Vol (10 day) 3N/A
Shares Outstanding 540.2M
Implied Shares Outstanding 6N/A
Float 20.95M
% Held by Insiders 132.48%
% Held by Institutions 10.00%
Shares Short (Jul. 14, 2021) 464.97k
Short Ratio (Jul. 14, 2021) 410
Short % of Float (Jul. 14, 2021) 4N/A
Short % of Shares Outstanding (Jul. 14, 2021) 40.16%
Shares Short (prior month Jun. 14, 2021) 468.38k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Sep. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-965.04%

Management Effectiveness

Return on Assets (ttm)-29.35%
Return on Equity (ttm)-86.20%

Income Statement

Revenue (ttm)1.98M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)17,742.50%
Gross Profit (ttm)92.14k
EBITDA -17.76M
Net Income Avi to Common (ttm)-23M
Diluted EPS (ttm)-0.9350
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)101.09k
Total Cash Per Share (mrq)0
Total Debt (mrq)1.18M
Total Debt/Equity (mrq)5.42
Current Ratio (mrq)0.55
Book Value Per Share (mrq)0.49

Cash Flow Statement

Operating Cash Flow (ttm)-14.56M
Levered Free Cash Flow (ttm)-3.85M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AVCN.TO
Avicanna
1 month ago
AVCN.TO
Avicanna
2 months ago
AVCN.TO
Avicanna
3 months ago
AVCN.TO
Avicanna
3 months ago
AVCN.TO
Avicanna
3 months ago
AVCN.TO
Avicanna
5 months ago
AVCN.TO
Avicanna
6 months ago
AVCN.TO
Avicanna
7 months ago
AVCN.TO
Avicanna
8 months ago
AVCN.TO
Avicanna
8 months ago
AVCN.TO
Avicanna
9 months ago
AVCN.TO
Avicanna
9 months ago
AVCN.TO
Avicanna
9 months ago
AVCN.TO
Avicanna
11 months ago
AVCN.TO
Avicanna
11 months ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago
AVCN.TO
Avicanna
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Sep 2020)Next Qtr. (Dec 2020)Current Year (2020)Next Year (2021)
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/A-0.34N/AN/A
Revenue EstimateCurrent Qtr. (Sep 2020)Next Qtr. (Dec 2020)Current Year (2020)Next Year (2021)
No. of Analysts1111
Avg. Estimate1M900k2.8M14M
Low Estimate1M900k2.8M14M
High Estimate1M900k2.8M14M
Year Ago SalesN/A123k168k2.8M
Sales Growth (year/est)N/A631.70%1,566.70%400.00%
Earnings HistoryInvalid Date2019-12-302020-03-302020-06-29
EPS Est.N/A-0.15-0.09-0.26
EPS ActualN/A-0.34-0.11-0.23
DifferenceN/A-0.19-0.020.03
Surprise %N/A-126.70%-22.20%11.50%
EPS TrendCurrent Qtr. (Sep 2020)Next Qtr. (Dec 2020)Current Year (2020)Next Year (2021)
Current Estimate0000
7 Days Ago-0.2-0.08-0.69-0.15
30 Days Ago-0.2-0.08-0.69-0.15
60 Days Ago-0.2-0.08-0.69-0.15
90 Days Ago-0.2-0.08-0.69-0.15
EPS RevisionsCurrent Qtr. (Sep 2020)Next Qtr. (Dec 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesAVCN.TOIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
32.48%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Avicanna Inc.


Avicanna Announces Change of Auditor

Avicanna Announces Change of Auditor

TORONTO, July 16, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the appointment of Kingston Ross Pasnak LLP (the “Successor Auditor”) as its independ... Read More...
Avicanna Executes Multi Year Agreement to Supply Brazilian Pharmaceutical Company with THC and CBD Cannabis Extracts

Avicanna Executes Multi Year Agreement to Supply Brazilian Pharmaceutical Company with THC and CBD Cannabis Extracts

Avicanna’s standardized CBD and THC Cannabis Extracts are to be utilized to produce a range of cannabis-derived products for the Brazilian market of 211 million people.Fulfillment of purchase orders based on preliminary forecasts for 2022 is expected to generate approximately CAD$4 million in revenue for Avicanna. /NOT FOR DISTRIBUTION TO... Read More...
Avicanna Financial Statement Update

Avicanna Financial Statement Update

TORONTO, June 30, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) announced today that the Company’s audit is ongoing and it expects to file the following periodic disclosure documents (collectively, the “Documents”) within the next sixty to seventy-five days: audited annual financial statements for the year ended December... Read More...
Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization

Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization

Initial development is part of a licensing and development agreement between the two companies to develop and deliver dermatology and cosmetic products.Combination of Avicanna’s intellectual property and Bio-Gate’s MicroSilver BG™ technology is aimed to target indications including eczema, acne, and atopic dermatitis. /NOT FOR DISTRIBUTIO... Read More...
Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, June 24, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that... Read More...
Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels

Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels

The two THC-Free RHO Phyto products will be available through the Medical Cannabis By ShoppersTM online portal and across specific adult use channels. Avicanna’s commercial products in Canada increase to 10 SKU’s where the CBD only oral products are targeted at patients, wellness focused consumers and new users who seek the benefits of CB... Read More...
Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes

Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, June 03, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) is announcing that it has commenced mailing its manag... Read More...
Avicanna's Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021

Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across cannabis channels nationwide in Canada. The initial launch of Pura Earth will include 3 products that will be available through Medical Cannabis by Shoppers™ online platform and across adult-use channels in Ontario... Read More...
Avicanna Announces Resignation of Board Member

Avicanna Announces Resignation of Board Member

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, May 07, 2021 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company... Read More...
Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital

Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital

Avicanna launches its initiative to supply major Canadian hospitals with its advanced RHO Phyto medical cannabis products supported by education, training, and patient support programs. Seven RHO Phyto products will be available for purchase at Sunnybrook Hospital’s Odette Cancer Centre pharmacy by patients that have been issued a written... Read More...
Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order

Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, April 26, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) is providing this bi-weekly update on the status of ... Read More...
Avicanna Announces Initial Listings and Sales for Evidence-Based RHO Phyto™ Products in Canada's Adult Use Channels Including Ontario, Manitoba, Saskatchewan, and New Brunswick

Avicanna Announces Initial Listings and Sales for Evidence-Based RHO Phyto™ Products in Canada’s Adult Use Channels Including Ontario, Manitoba, Saskatchewan, and New Brunswick

Expanding from the successful nation-wide launch in medical-only channels through Medical Cannabis by Shoppers Drug Mart™ the company set out to rapidly commercialize its RHO Phyto products through retail channels and has succeeded in doing so within a three-month period.In collaboration with Velvet’s sale infrastructure, the RHO Phyto pr... Read More...
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update

Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, April 12, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) announces that, further to its March 29, 2021 news r... Read More...
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, March 29, 2021 -- Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN) announces that it will miss the deadline (the “Filin... Read More...
Avicanna's Majority Owned Colombian Subsidiary Attains 2021 THC Production Quota and Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Chile

Avicanna’s Majority Owned Colombian Subsidiary Attains 2021 THC Production Quota and Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Chile

Avicanna has been granted its 2021 quota from the Colombian government to cultivate and process up to 10,267 kg of dry flower for exports in the form of crude and standardized extracts and final phyto-therapeutic pharmaceutical products and to produce seeds from registered psychoactive varieties for commercial purposes.This is the first k... Read More...
Avicanna to Participate in Benzinga Biotech Small Cap Conference and the Virtual Life Sciences Investor Forum Both Taking Place on Thursday March 25th

Avicanna to Participate in Benzinga Biotech Small Cap Conference and the Virtual Life Sciences Investor Forum Both Taking Place on Thursday March 25th

TORONTO, March 25, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Avicanna’s Chief Executive Officer, Aras Azadian has been invited to... Read More...
Avicanna Enters Strategic Partnership with Al Harrington's, Viola, for commercialization of Viola branded products in Canada

Avicanna Enters Strategic Partnership with Al Harrington’s, Viola, for commercialization of Viola branded products in Canada

Purpose-driven cannabis brand rooted in social equity and justice to enter CanadaAvicanna to lead commercialization through medical and consumer retail sales channels Viola intends to promote various social projects to advance education related to cannabis as well as Viola’s pioneering initiatives to promote diversity, equity, and inclusi... Read More...
Avicanna to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Avicanna to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

TORONTO, March 17, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Avicanna’s Chief Executive Officer, Aras Azadian has been invited to... Read More...
Avicanna Enters Multi-level Strategic Partnership with Al Harrington's, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada and the United States

Avicanna Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada and the United States

Development and licensing of a bespoke and evidence-based athletic line of CBD topical products for the re+PLAY brand in the U.S.Avicanna to lead commercialization in Canada through consumer retail and medical sales channels. /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO... Read More...
Avicanna Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies

Avicanna Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies

RHO Phyto Deep Tissue Gels will be initially available on the Medical Cannabis by Shoppers Drug Mart™ online platform and expanded into specific consumer retail channels in February 2021.Initiation of osteoarthritis preclinical trials in Canada in addition to the enrollment of the products into the UHN MC-RWE study to evaluate the effecti... Read More...
Avicanna Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates

Avicanna Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates

TORONTO, Jan. 21, 2021 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the U... Read More...
Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health Network and GMP Manufacturing of its First Pharmaceutical Preparation

Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health Network and GMP Manufacturing of its First Pharmaceutical Preparation

The multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at UHN is also supported by a Mitacs Accelerate program grant.UHN scientists will be analyzing Avicanna’s RHO Phyto™ cannabinoid-based products for their efficacy on comorbidities and seizure c... Read More...
Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada

Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada

Expanding from the successful launch in medical-only channels in partnership with Medical Cannabis by Shoppers, Avicanna will now offer RHO Phyto™ nationwide through provincial retailers RHO Phyto products will include its advanced formulary of sublingual sprays, oil drops and topicals through retail sales channels estimated at $3 billion... Read More...
Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay

Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay

Partnership with Alliancepharma Technologies S.A., one of Ecuador’s largest pharmaceutical companies, will take advantage of the upcoming cannabis regulations to allow for the registration and distribution of several of Avicanna’s consumer and pharmaceutical products across EcuadorDistribution agreement with Spenta S.A., an Ecuadorian cos... Read More...
Avicanna Launches Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia

Avicanna Launches Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/Leveraging the successful launch of the Company’s RHO Phyto™ branded advanced medical cannabis product line in Canada, the portfolio of ... Read More...
Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Aras Azadian, Chief Executive Officer of Avicanna, commented "We are thrilled to report the tremendous progress our team continues to make in our commercialization and research efforts. During the third quarter, we were able to demonstrate the superiority of our technologies and products with several strategic commercial partnerships but... Read More...
Avicanna Enters Agreement to Develop and License Cannabinoid Tablet Formulations for US Distributor Partner

Avicanna Enters Agreement to Develop and License Cannabinoid Tablet Formulations for US Distributor Partner

The agreement showcases Avicanna's expertise in cannabinoid product development and drug delivery across several delivery mechanisms/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/TORO... Read More...
Avicanna's RHO Phyto™ Rapid Act Sprays are Now Available Nation Wide in Canada Through Medical Cannabis by Shoppers™

Avicanna’s RHO Phyto™ Rapid Act Sprays are Now Available Nation Wide in Canada Through Medical Cannabis by Shoppers™

Avicanna's RHO Phyto product line is now commercially available after years of research and development through collaborations with world class academic and clinical organizations. The development of RHO Phyto products has focused on the key properties in drug development that health care providers seek when recommending a medical produc... Read More...
Avicanna's subsidiary obtains GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia

Avicanna’s subsidiary obtains GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/Authorized cannabinoid products will be available to the medical community and patients in early Q4 2020 including Avicanna's advanced o... Read More...
Avicanna Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements

Avicanna Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/TORONTO, Sept. 4, 2020 - Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company fo... Read More...
MediPharm Labs Launches New Sublingual Sprays for Sale via Medical Cannabis by Shoppers™ Under Agreement With Avicanna

MediPharm Labs Launches New Sublingual Sprays for Sale via Medical Cannabis by Shoppers™ Under Agreement With Avicanna

BARRIE, Ontario, Aug. 26, 2020 -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly-owned subsidiary, MediPharm Labs Inc., has launched a... Read More...
Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany as well as Industrial Scale THC Quota Granted by the Colombian Authorities

Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany as well as Industrial Scale THC Quota Granted by the Colombian Authorities

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ The export of the CBG isolates into the United States is part of the first known industrial cultivation, extraction, and purification... Read More...
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/Successfully launched advanced "medical cannabis 2.0" products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by ... Read More...
Avicanna and Red White & Bloom Enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived CBD-Based Topical Products in the United States

Avicanna and Red White & Bloom Enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived CBD-Based Topical Products in the United States

The partnership allows for both companies to stake a claim in the expanding $532 billion beauty industry with the most advanced and only clinically backed CBD skin care line/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLAT... Read More...
Red White & Bloom and Avicanna enter into exclusive partnership for the distribution and commercialization of Pura H&W CBD-based Topical Products in the United States

Red White & Bloom and Avicanna enter into exclusive partnership for the distribution and commercialization of Pura H&W CBD-based Topical Products in the United States

Pura H&W ProductsPura H&W ProductsPura H&W ProductsPartnership allows for both companies to stake a claim in the expanding $532 billion beauty industry with the most advanced and only clinically backed CBD skin care line;Product line synergistically combines natural ingredients with CBD in advanced and proprietary formulations... Read More...
1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph

1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph

In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation Avicanna further expands its existing neurobiological research collaboration with ... Read More...
Avicanna Announces Participation in a Medical Cannabis Real-World Evidence (MC-RWE) Research Study Led by the University Health Network in Partnership with Medical Cannabis by Shoppers™ using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products

Avicanna Announces Participation in a Medical Cannabis Real-World Evidence (MC-RWE) Research Study Led by the University Health Network in Partnership with Medical Cannabis by Shoppers™ using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products

The Rho Phyto portfolio contains a full formulary of products including oil drops, sublingual sprays, capsules, and topicals that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data which will be available exclusively on the Medical Cannabis by Shoppers™ online portal by the end of July 2020 .T... Read More...
Avicanna Announces Co-development of a Cannabinoid-based Formulation for Treatment of COVID-19 related Lung Inflammation with Support from the Mitacs Accelerate Program

Avicanna Announces Co-development of a Cannabinoid-based Formulation for Treatment of COVID-19 related Lung Inflammation with Support from the Mitacs Accelerate Program

Avicanna further expands its existing research collaboration with Dr. Christine Allen's Research Group at the University of Toronto to include the development of a cannabinoid-based pharmaceutical for the treatment of COVID-19 induced lung inflammationThis project proposal has been peer-reviewed and has successfully obtained funding from ... Read More...
Avicanna to Host Virtual Symposium Titled "Medical Cannabis 2.0" on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line

Avicanna to Host Virtual Symposium Titled “Medical Cannabis 2.0” on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line

- - -The symposium will present the evolution of medical cannabis including the Avicanna-led advancements in R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers. - - - This year's annual symposium coincides with the expected launch of Avicanna's RHO Phyt... Read More...
Coming Soon.

Delayed data (1h)


Share this page